Database on Blood Safety 2009 in ECO Member States

Similar documents
The establishment of well-organized, nationally-coordinated blood transfusion services with quality systems in all areas

Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey

WHO/EHT/ Global Database on Blood Safety

Guide to the preparation, use and quality assurance of blood components

2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies

Duration: 12 months May to April

L 256/32 Official Journal of the European Union

The testing of Donated Blood and Components at NHSBT

Non-reproductive tissues and cells Recommending authority/ association

Blood transfusion. Dr. J. Potgieter Dept. of Haematology NHLS - TAD

Inspections, Compliance, Enforcement, and Criminal Investigations. Central Texas Regional Blood & Tissue Center 07-Nov-03

A. Anti-HIV-1/2, HIV NAT Lookback: for those identified blood and blood components collected:

Guidance for Industry

SOP 17 BLOOD BANK. 3. Overall Responsibility: Blood Bank In-Change/Pathologist.

Cataloguing-in-Publication (CIP) data. CIP data are available at

Pretransfusion Testing

TRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION:

PROPOSED TECHNICAL REQUIREMENTS BLOOD AND BLOOD COMPONENTS. File 1 DRAFT FOR CONSULTATION PURPOSES ONLY

Non-reproductive tissues and cells

Jovona Powelson, B.S. MLT (ASCP) Director of Laboratories

Human tissues and cells annual report 2011

Blood Screening. Technology Opportunity Assessment. Prepared for the Merck for Mothers Program. February

Transfusion Medicine in Saudi Arabia

Il ruolo delle VEQ per la sicurezza trasfusionale

Non-reproductive tissues and cells Recommending authority/ association

Essential Medicines. WHO

TGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview

HUNGARIAN NATIONAL BLOOD TRANSFUSION SERVICE. Dr. Klara Baroti-Tóth, PhD IPFA/PEI 19 th International Workshop Budapest, May, 2012.

The New Regulations - Special IVD Issues

Independent Assurance Statement by Bureau Veritas

Strengthening Health Systems and Blood Services

NATIONAL BLOOD TRANSFUSION SERVICES STRATEGY


HEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS. Joana Bikulčienė Director of National blood center

Non-reproductive tissues and cells Recommending authority/ association

Universal Access to Safe Blood Transfusion

Autologous plasma eye drops. Patient information

2014/LSIF/PD/008 Building Blocks and Challenges to Implementing a National Blood Program in Malaysia

Version for the Silent Procedure 29 April Agenda item January Hepatitis

Plasma for fractionation: South African Plasma Requirements

INSTRUCTIONS FOR BLOOD BANK INSPECTION CHECKLIST AND REPORT CMS-282

APPROACH TO RISK MANAGEMENT IN MEDICAL PRACTICE: STANDPOINT OF THE BLOOD TRASFUSION*

Non-reproductive tissues and cells

For information only: all participants in the graduated plan procedure. 7 January 2013

KINGDOM OF CAMBODIA National guidelines for transfusion practice

Executive Summary for Executive Licensing Panel 20 May Dr Kamal Ahuja. Follow-up inspection 14 April 2010

Non-reproductive tissues and cells

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL

UNIVERSITY OF WASHINGTON MEDICAL CENTER Men s Health Center and Male Fertility Laboratory Sperm & Testis Cryopreservation Program Patient NAME and ID

WORLD HEALTH ORGANIZATION. Blood safety: proposal to establish World Blood Donor Day

Screening donors and donations for transfusion transmissible infectious agents. Alan Kitchen

donors and collecting blood and plasma in for-profit or a not for profit environment

Study of ChLIA and ELISA for TTI Markers in Blood Donors

2015 Annual Report Taiwan Blood Services Foundation

INDONESIAN EXPERIENCE IN PRODUCING MINIPOOL CRYOPRECIPITATE. Yuyun SM Soedarmono

BLOOD SAFETY STATUS IN INDONESIA. Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013

Haemovigilance in Europe: What do health authorities expect from haemovigilance?

Non-reproductive tissues and cells

This follows similar work previously conducted by Bureau Veritas for Nestlé S.A. in other global operations.

Source of effectiveness data Effectiveness data were derived from a single study combined with a review of previously completed studies.

Structure and duties of Blood service

Guidance for Industry

BLOOD DONATION AND TRANSFUSION

EZER MIZION PROCEDURES FOR TRANSPLANT CENTERS AND COOPERATIVE REGISTRIES

41st DIRECTING COUNCIL

Screening Donated Blood for Transfusion Transmissible Infections in Bangladesh

QSEAL Recovered Plasma Specification

Frequently Asked Questions on Blood Donation

NANDTB-F012 Rev 0 Audit Checklist

CORD BLOOD TRANSPLANTATION STUDY CBU EXCLUSION AND QUARANTINE RELEASE FORM

Answering your daily challenges. in the ELISA technology I N FECTI OUS DISEASES. bioelisa

to be notified: all parties involved in the graduated plan procedure. Annexes

The Collection, Testing and Use of Blood and Blood Components in Europe

Survey questionnaire on STI. surveillance, care and prevention. in European countries SAMPLE APPENDIX

2014 report. The collection, testing and use of blood and blood components in Europe. M.P. Janssen 1 and G. Rautmann 2

Guidelines for Use of Canine Blood Components

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P

Statement from International Transfusion Medicines Experts

Accreditation in the Philippines

BLOOD TRANSFUSION. Dr Lumka Ntabeni

Lookback studies to assess viral risks The French experience

GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS

Blood Components & Indications for Transfusion. Neda Kalhor

Donor Screening in The Region. Vincini GA NRL, Melbourne, Australia

DONOR RECRUITMENT AND PLASMA COLLECTION IN INDONESIA. Yuyun SM Soedarmono Blood Services Committee Ministry of Health of Indonesia 1

EUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY

Non-reproductive tissues and cells

Blood Transfusion. What is blood transfusion? What are blood banks? When is a blood transfusion needed? Who can donate blood?

National Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands. TransMed conference Bhopal 18 November 2016

The Italian blood system: an overview with special focus on plasma production and plasma-derived medicinal products

Better Blood Transfusion Level 2 BLOOD COMPONENT USE. Self-Directed Learning Pack

Overview of Blood Transfusion System of Iran:

Juventas SHARING LIFE CONSENT FOR PLASMA INFUSION

Keeping blood transfusions safe:

Public Health, Infections and Transplantation

Case 1. FDA, Legal, and EBAA Medical Standards Panel. Case 1. Case 1 6/25/2012. Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies

Answers. To Your. Questions

CERTIFIED MAIL RETURN RECEIPT REQUESTED. Esther Hernandez President United States Blood Bank, Inc NW 95th Avenue Miami, Florida

Transcription:

Database on Blood Safety 2009 in ECO Member States Section 1: Administrative Information Information provided by: 1.1 Name: 1.2 Title: 1.3 Position: 1.4 Organization: 1.5 Address: 1.6 Country: 1.7 Tel. no. 1.8 Fax. no. 1.9 E-mail: 1.10 Date: 1.11 1.12 Please provide data for the period January 2009 to December 2009. If data for this period are not available, please provide data for the period January 2008 to December 2008. Attach additional sheets, if necessary. Data provided for the year (please tick appropriate box): 2008 2009 The information given applies to blood pragrammes at the following level: National level State/ regional/ provincial level other (please If not national, what percentage of your country's blood programme does this 1.12.1 report cover? 1.13 Total number of whole blood units collected in the reporting year: Section 2: Organization and Management 2.1 Is there a unit within the Ministry of Health (or other government department) with responsibility for the national blood programme? 2.2 Is there a designated national blood programme manager? Is there a national blood authority/ commission (or 2.3 equivalent)? 2.4 Is there a national blood policy? 2.4.1 If yes, year of adoption: Is there a national blood transfusion service 4 (NBTS)? If yes, in which year was the NBTS established? 2.5 Is there a national director/chief executive officer 2.5.1 for the NBTS? Is there an NBTS management committee? Has the government delegated any responsibility for the NBTS/blood transfusion services 5 to a nongovernmental 2.6 organization? 2.6.1 If yes: Name of the organization(s): role of the organization(s): How is the responsibility for the operation of the NBTS/blood transfusion services 5 distributed? For each category, please indicate the number of different types of blood centre 2.7 Government None-governmental/non-profit organizations 2.8 Does any international agency/organization/institution Commercial (for profit) organizations I

2.9 2.10 2.11 2.12 2.13 2.14 provide technical support to NBTS/blood transfusion services? 2.8.1 If yes, name of agency: Does any international agency/organization/institution provide financial support to NBTS/blood transfusion services? 2.9.1 If yes, name of agency: Is there a system of centralized data collection and analysis for the NBTS/blood transfusion services? Are there national standards for the collection, storage, processing and issue of blood and blood products? Is there a designated national quality manager 6 for blood transfusion services? Is there a system of audit 8 in the NBTS/blood transfusion services? Is there an educational programme in blood transfusion medicine/science leading to a nationally-recognized university degree/diploma? 2.15 Is there a system of regular training of staff? 2.16 Is there a national haemovigilance 10 system? Section 3: Blood Donors and Blood collection 3.1 3.2 Is there a unit designated for the national blood donor recruitment programme? In 2007, what percentage of donors were deferred after being assessed as unsuitable to donate blood? In 2007, how many units of whole blood were collected from the following types of blood donors 11? Voluntary non-remunerated donors N o Family/replacement donors Paid donors 3.3 Autologous donors How many units of whole blood were collected from the following types of voluntary nonremunerated blood donors 11? N o 3.3.1 New voluntary donors Lapsed voluntary donors Regular voluntary donors What was the approximate percentage of all donations from: 3.3.2 Male donors Female donors 3.4 What percentage of blood centres collect whole blood units in sterile, disposable, plastic blood collection bags? Is the prevalence of transfusion transmissible infections monitored in 3.5 the blood donor population? 3.6 What percentage of blood centres have a system of post-donation councelling blood donors who test II

positive for transfusion transmissible infections? Section 4: Screening 4.1 4.2 Is there a national strategy for screening donated blood units for transfusion-transmissible infections? Infection HIV I/II HBV HCV Syphilis Chagas disease Marker(s) Tested Ag Combined Ag + DNA/RNA HBsAg Anti-HBc Combined Ag + DNA/RNA Ag Donations Molecular Simple/ Yes Tested EIA (e.g.nat, Rapid TMA) Malaria HTLVI/II Other (please Other (please Ag DNA/RNA 4.3 In 2007, what was the prevalence (in percentage) of infection in donated blood units from different types of blood donor? Infection All Donors Total Voluntary New Voluntary Lapsed voluntary Regular voluntary Family Replacement Paid donors III

Donors Donors Donors donors Donors HIV HBV HCV Syphilis Chagas disease Malaria HTLV Other (please Other (please 4.4 4.5 From which tests are prevalence data obtained? No Screening tests Confirmatory tests In 2007, what was the total percentage of blood discarded after screening for transfusion-transmissible infections? Section 5: Blood group serology and compatibility testing 5.1 Is there a national strategy for testing donated blood units for blood groups? 5.2 What percentage of donations are tested for blood group and by which methodology? Test performed Percentage tested Manual method Semi- Automated Fully Automated ABO cell grouping ABO serum grouping RhD antigen testing Antibody screening Other blood groups 5.3 Are there national guidelines on compatibility testing? 5.4 What percentage of blood units are issued annually without compatibility testing? IV

Section 6: Blood component preparation, storage and transportation 6.1 What percentage of blood centres prepares blood components? 6.2 What percentage of blood centres has the following equipment? Blood bank refrigerator with temperature monitoring system and alarm Plasma freezer Platelet agitator/incubator Refrigerated centrifuge Standby generator Blood transport boxes 6.3 In 2007, what percentage of whole blood units were separated into components? 6.4 Which blood components are prepared? Component Prepared from whole blood Prepared by Apheresis Red cell preparations Platelet concentrates Plasma Fresh frozen plasma Cryoprecipitate Inactivated plasma Small paediatric units Leucocyte-reduced units Peripheral blood stem cells (please 6.5 What percentage of blood centres prepares blood components by apheresis? 6.7 What percentage of blood centers transport blood and blood components in temperature monitored equipment? 6.8 What percentage of blood centres has a system of separate blood storage areas for quarantine13 and the issue of blood components? Section 7: The clinical use of blood and blood components 7.1 Are there national guidelines on the appropriate clinical use of blood? 7.2 In 2007, approximately how many patients received a transfusion of blood or blood components? 7.3 What percentages of hospitals have a system for monitoring clinical transfusion practice? 7.4 What percentages of hospitals have a system for monitoring posttransfusion reactions? 7.5 What percentages of hospitals have a system for monitoring posttransfusion infections? V

Section 8: Fractionated plasma products 8.1 Is there a national strategy for the provision of fractionated plasma products 15? 8.1.1 If yes: Imported from abroad Fractionated within the country Public/not-for-profit sector If yes, please specify the name of the organization: Private/for-profit sector Contract fractionation: If yes, please specify: Name of the organization: Country: 8.2 What is the total volume of plasma designated nationally for fractionation in a year? Recovered plasma Litres Apheresis plasma Litres Not applicable 8.3 Which products are manufactured by fractionation within the country? Albumin Immunoglobulin Factor VIII Factor IX (please : 8.4 What is the percentage of different types of plasmapheresis donors? Voluntary non-remunerated plasma donors Paid plasma donors Other plasma donors (please : VI

GLOSSARY 1 National blood programme: The government programme with overall responsibility for planning, implementation and monitoring of all activities related to blood transfusion throughout the country. Responsibility for the implementation of the blood programme may be fully or partially delegated to a governmental or non-governmental organization designated as the national blood transfusion service. 2 National blood authority/commission: The highest policy formulation and decision-making body under the national health authority for issues pertaining to blood transfusion services in the country. All major stakeholders in the blood transfusion process are usually represented in this authority. 3 National blood policy: A statement of intent by the national health authority that defines the organizational, financial and legal measures that will be taken to ensure the quality, safety, availability and accessibility of blood transfusion within the country. 4 National blood transfusion service (NBTS): The organization with statutory national responsibility for the provision of blood for transfusion and liaison with clinical services for the appropriate use of blood for patient care. The NBTS coordinates all activities concerned with blood donor recruitment and the collection, testing, processing, storage and distribution of blood and blood products, the clinical use of blood and surveillance of adverse transfusion events. Activities are carried out within a network of national/regional/provincial blood centres and hospital blood banks. 5 Blood transfusion services: Hospitals and other facilities involved in the provision of blood in countries where there is no National Blood Transfusion Service. 6 Quality manager: The appointed, responsible and authorized individual within an organization with responsibility for developing and managing the quality system. 7 Standard operating procedure: Local written instructions for the performance of a specific procedure. 8 Audit: Systematic, independent and documented examination to determine whether activities comply with a planned and agreed quality system. 9 External quality assessment (EQA): The external assessment of a laboratory s performance using samples of known, but undisclosed, content and comparison with the performance of other laboratories. An external quality assessment scheme is a recognized scheme for organizing EQA. This can be a local scheme or may be organized at national, regional or international level. 10 Haemovigilance: The monitoring, reporting and investigation of adverse incidents/near-misses related to all blood transfusion activities. 11 Blood donors Voluntary non-remunerated blood donor: An altruistic donor who gives blood freely and voluntarily without receiving money or any other form of payment. New voluntary donor: A voluntary non-remunerated blood donor who has never donated blood before. Lapsed voluntary donor: A voluntary non-remunerated blood donor who has given blood in the past but does not fulfil the criteria for a regular donor. Regular voluntary donor: A voluntary non-remunerated blood donor who has given blood at least three times and who continues to donate blood at least once a year. Family/replacement blood donor: A donor who gives blood when it is required by a member of the patient's family or community. This may involve a hidden paid donation system in which the donor is paid by the patient's family. Paid donor: A donor who gives blood for money or other form of payment. Autologous donor: A patient who donates his/her blood to be stored and reinfused, if needed, during surgery. 12 NAT: Nucleic acid testing. 13 Quarantine: Non-authorization to proceed to next stage of a process until specified standards or conditions are met. 14 Maximum surgical blood ordering schedule (MSBOS): A guide to expected normal blood usage for elective surgical procedures which lists the number of units of blood to be routinely crossmatched or grouped, screened and held for each procedure preoperatively. 15 Fractionated plasma products: Human plasma protein products prepared under pharmaceutical manufacturing conditions. Plasma products include albumin, immunoglobulin and coagulation factors VIII and IX. VII